ArticleAntimicrobial agents and chemotherapy2019
Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Virulence and resistance factors of Nakaseomyces glabratus (formerly known as Candida glabrata) in Europe: A systematic review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Neonatal Fungemia by Non-Candida Rare Opportunistic Yeasts: A Systematic Review of Literature.International journal of molecular sciences · 2024Pooled it
- The repertoire of yeast species from human clinical samples in the United Kingdom 2016-2022: epidemiology, clinical relevance, and fluconazole resistance.Microbiology spectrum · 2026Article
- High burden of Candida blankii (syn.Tardiomyces blankii) bloodstream infections among neonates in an intensive care unit in Bangladesh.BMC infectious diseases · 2026Article
- Antifungal Susceptibility of Rare Yeasts Causing Vulvovaginal Candidiasis in the Acidic Vaginal Environment.Infection and drug resistance · 2026Article
- Antifungal treatment strategies and their impact on resistance development in clinical settings.The Journal of antimicrobial chemotherapy · 2025Review
- Name changes for fungi of medical importance, 2022-2024.Journal of clinical microbiology · 2025Review
- Molecular identification and antifungal susceptibility profile of rare and emerging yeast species causing onychomycosis.BMC research notes · 2025Article
- Clinical isolation, biofilm formation, and pathogenicity analysis of different species of theFrontiers in microbiology · 2025Article
- First Report ofInfection and drug resistance · 2025Article
- Antifungal susceptibility profile of Candida species and uncommon yeasts from drug abusers with oral candidiasis.BMC oral health · 2024Article
- Diversity and Antifungal Susceptibilities of Yeasts from Mangroves in Hong Kong, China-A One Health Aspect.Journal of fungi (Basel, Switzerland) · 2024Article
- The yeast genus Tardiomyces gen. nov. with one new species and two new combinations.Infection · 2024Article
- Antifungal Susceptibility Data and Epidemiological Distribution ofAntibiotics (Basel, Switzerland) · 2024Article
- Occurrence of pathogenic yeastF1000Research · 2024Article
- Changes in fungal taxonomy: mycological rationale and clinical implications.Clinical microbiology reviews · 2023Review
- Review
- Clinical, Microbiological, and Molecular Characterization of Candia (Starmera) stellimalicola, a Rare Fungal Pathogen Causing Human Infections.Mycopathologia · 2023Article
- Name Changes for Fungi of Medical Importance, 2020 to 2021.Journal of clinical microbiology · 2023Review
- Overview on the Infections Related to RarePathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The triazole drug fluconazole remains one of the most commonly prescribed antifungal drugs, both for prophylaxis in high-risk patients and also as a second-line treatment option for invasive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.